Business Context and Reporting Period
This Form 8-K, dated September 14, 2026, reports on the proposed acquisition of BIO-TECHNE Corp by Merck KGaA, Darmstadt, Germany. The company entered into a Merger Agreement on June 25, 2026, with a special shareholder meeting scheduled for September 23, 2026. The filing primarily addresses litigation regarding the merger and provides supplemental disclosures to the previously filed Proxy Statement.
Key Financial Metrics
While this filing does not report current period revenue or operating results, it discloses specific financial figures used in the financial advisor's valuation analysis as of March 31, 2026, and June 19, 2026:
- Debt: Approximately $200 million (total debt as of March 31, 2026).
- Cash and Equivalents: Approximately $210 million.
- Investments: Includes approximately $231 million in Wilson Wolf, $15 million in Spear Bio, $11 million in divestiture-related notes receivable, and $1 million in MDxHealth.
- Adjusted EBITDA: Approximately $421 million (LTM Core as of March 31, 2026).
- Share Count: Approximately 157.0 million to 157.8 million fully diluted shares (as of June 19, 2026).
- Projected Net Debt: Projected to be approximately $110 million (FY 2027), $(192) million (FY 2028), and $(551) million (FY 2029).
Material Changes and Litigation
The filing discloses the following material developments since the initial Proxy Statement:
- Litigation: A lawsuit titled Robert Garfield v. Baumgartner et al. was filed on September 9, 2026, in Minnesota District Court. The plaintiff alleges the Proxy Statement omitted material information and seeks to enjoin the shareholder vote. Additionally, multiple demand letters have been received alleging deficient disclosures.
- Supplemental Disclosures: Bio-Techne voluntarily supplemented the Proxy Statement to address these claims, denying the allegations but seeking to avoid delays. Key updates include:
- Details of preliminary discussions with "Party A" and "Party B" dating back to 2023, including verbal expressions of interest from Merck in Q2 2023 at prices of $92 to $95 per share.
- Confirmation that no post-closing employment arrangements were discussed between July 2025 and the Merger Agreement signing.
- Clarification on the engagement of Goldman Sachs and relationship disclosures.
Outlook, Risks, and Management Commentary
Management Commentary: Bio-Techne maintains that the original Proxy Statement complied with all laws and that the allegations in the lawsuit are without merit. However, the company chose to supplement disclosures to prevent potential delays to the merger vote.
Valuation Ranges: Goldman Sachs provided illustrative valuation ranges based on various methodologies:
- Present Value Analysis: $58 to $72 per share.
- Implied Future Value Analysis: $45 to $74 per share (discounted to March 31, 2026).
- Trading Multiples Analysis: $49 to $67 per share.
Risks: The filing highlights significant risks including the failure to obtain shareholder approval, integration difficulties, potential loss of key employees, disruption of operations, and the possibility of competing offers. It also notes the risk that the transaction may not be completed or may be delayed due to legal proceedings.
Investor Verification Checklist
- Verify the status of the Robert Garfield v. Baumgartner et al. lawsuit and whether an injunction has been granted prior to the September 23, 2026, shareholder meeting.
- Review the full Proxy Statement to understand the complete terms of the Merger Agreement and the specific offer price per share (not explicitly stated in this 8-K summary).
- Confirm the final vote results of the special shareholder meeting scheduled for September 23, 2026.
- Assess the impact of the disclosed preliminary discussions with "Party A" and "Party B" on the negotiation process and final valuation.
- Monitor for any further updates regarding the integration plan and post-closing employment arrangements for executive officers.